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Tanner B. Pollock1, Giovan N. Cholico1, Noail F. Isho2, Ryan J. Day2, Tarun Suresh1,
Erica S. Stewart1, Madyson M. McCarthy1 and Troy T. Rohn1*
1 Department of Biological Sciences, Boise State University, Boise, ID, United States, 2 Health Sciences Department,
University of Washington School of Medicine, Seattle, WA, United States
Despite the fact that harboring the apolipoprotein E4 (APOE4) allele represents the
single greatest risk factor for late-onset Alzheimer’s disease (AD), the exact mechanism
by which ApoE4 contributes to disease progression remains unknown. Recently, we
demonstrated that a 151 amino-terminal fragment of ApoE4 (nApoE41−151) localizes
within the nucleus of microglia in the human AD brain and traffics to the nucleus
causing toxicity in BV2 microglia cells. In the present study, we examined in detail what
genes may be affected following treatment by nApoE41−151. Transcriptome analyses
in BV2 microglial cells following sublethal treatment with nApoE41−151 revealed the
upregulation of almost 4,000 genes, with 20 of these genes upregulated 182- to 715-
fold compared to untreated control cells. The majority of these 20 genes play a role in
the immune response and polarization toward microglial M1 activation. As a control,
an identical nApoE31−151 fragment that differed by a single amino acid at position
112 (Cys→Arg) was tested and produced a similar albeit lower level of upregulation
of an identical set of genes. In this manner, enriched pathways upregulated by
nApoE31−151 and nApoE41−151 following exogenous treatment included Toll receptor
signaling, chemokine/cytokine signaling and apoptosis signaling. There were unique
genes differentially expressed by at least two-fold for either fragment. For nApoE31−151,
these included 16 times as many genes, many of which are involved in physiological
functions within microglia. For nApoE41−151, on the other hand the number genes
uniquely upregulated was significantly lower, with many of the top upregulated genes
having unknown functions. Taken together, our results suggest that while nApoE31−151
may serve a more physiological role in microglia, nApoE41−151 may activate genes
that contribute to disease inflammation associated with AD. These data support the
hypothesis that the link between harboring the APOE4 allele and dementia risk could be
enhanced inflammation through activation of microglia.
Keywords: apolipoprotein E4, microglia cells, BV2 cells, Alzheimer’s disease, inflammation, toxicity, RNA-seq, M1
phenotype
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia
and is classified as a progressive, neurodegenerative disease
whose symptoms include loss of memory and higher executive
functioning (DeTure and Dickson, 2019). A prominent factor
for late-onset AD is apolipoprotein E (ApoE), a lipoprotein
transporter encoded by a single gene with three alleles (APOE2,
E3, and E4). The APOE4 allele is found in approximately
40% of AD patients and represents the greatest genetic risk
factor for late-onset AD (Raber et al., 2004). In contrast,
harboring the APOE3 allele is neutral in dementia risk even
though this version differs by only a single amino acid from
ApoE4, having a cysteine at position 112 instead of arginine
(Raber et al., 2004). A central question is how does this
single amino acid difference account for dementia risk on a
molecular level?
Studies have suggested that the key could be enhanced
proteolysis of ApoE4 into fragments that have a toxic-gain
of function (Rohn, 2013). Thus, ApoE4 is proteolyzed more
readily than ApoE3, and fragments of ApoE4 are more
prevalent in the brains of AD patients (Huang et al., 2001;
Rohn et al., 2012; Rohn, 2013). Recently, we extended these
findings by demonstrating that an amino-terminal fragment
of ApoE4 (nApoE41−151) generated following cleavage of full-
length ApoE4 by extracellular cellular proteases including MMP-
9 is taken up by microglia, targets to the nucleus, and can
induce cytotoxicity (Love et al., 2017). We also found the
presence of this fragment in the nucleus of microglia in both
E4/E4 and E3/E3 cases of postmortem AD brain sections (Love
et al., 2017). Our hypothesis is that nApoE41−151 acts as a
transcription factor leading to the expression of genes that
promote microglia activation (Pollock et al., 2019). In the
present study we examined this possibility by utilizing BV2
microglia cells and demonstrated that sublethal concentrations
of nApoE41−151 promoted upregulation of thousands of genes,
many linked to the functioning of the immune system and
microglia activation. Surprisingly an identical nApoE31−151
fragment (differing by one amino acid at position 112, C→R)
also led to an upregulation of many of the same genes as
nApoE41−151. These results suggest a novel role for ApoE
and further, potentially link harboring the APOE4 allele to
inflammation and degeneration that has long been associated
with AD (Streit, 2005; Graeber and Streit, 2010; Heneka et al.,
2014; Das and Chinnathambi, 2019).
MATERIALS AND METHODS
Materials
Construction and purification of the amino-terminal fragments
1–151 for ApoE4 (nApoE41−151) or ApoE3 (nApoE31−151) was
contracted out to GenScript (Piscataway, NJ, United States). For
both fragments, a 6X-His tag was coupled to the fragments
to facilitate purification. Mouse CXCL2 or IL-12β quantikine
ELISA kits were purchased from R&D Systems (Minneapolis,
MN, United States).
Cell Culture of BV2 Cells
BV2, murine microglial cells, were maintained at 37◦C and
6% CO2 in a humidified incubator. Cells were maintained
in RPMI 1640 Media (Hyclone) supplemented with 10%
standard fetal bovine serum (Hyclone), 10% Cellgro MEM Non-
essential Amino Acid (Corning) and 10% Penicillin streptomycin
(Hyclone). Cells were cultured in 50 mL T25 Flasks. All supplies
were purchased from ThermoFisher Scientific Inc. (Waltham,
MA, United States). Treatment of BV2 cells was undertaken
by incubation with nApoE31−151 or nApoE41−151 fragments
diluted in conditioned media at a concentration of 25 µg/ml for
5 h to assess mRNA expression. Control cells (untreated) had an
equivalent amount of conditioned media added to the wells.
Total RNA Extraction and cDNA
Synthesis in BV2 Microglia Cells
Total RNA was extracted from cells with the Direct-zol RNA
MicroPrep Kit (Zymo Research Corp., CA, United States)
according to manufacturer’s instructions. Genomic DNA
was eliminated using TURBO DNAse as described by
the manufacturer (Life Technologies, CA, United States).
RNA quality was assessed using spectrophotometry and
gel electrophoresis. Total cDNA was generated from 1 (µg
of total RNA using qScript cDNA SuperMix (QuantaBio,
MA, United States). Prior to use in qPCR, cDNA was
diluted 1:2 with water.
CXCl2 and IL-12b Quantitative PCR
Primers were designed to specifically amplify a portion of either
the IL-12β or CXCL2 genes. Serine/arginine-rich splicing factor
11 (SFRS11) and EH domain-binding protein 1 (EHBP), two
ultraconserved elements that have invariant copy number in
mice, were used as reference genes. All primers were synthesized
by Integrated DNA Technologies (Coralville, IA). For Il12β,
the forward sequence was TGGTTTGCCATCGTTTTGCTG and
the reverse was ACAGGTGAGGTTCACTGTTTCT. For CXCL2,
the forward sequence was CGCTGTCAATGCCTGAAGAC and
the reverse was ACACTCAAGCTCTGGATGTTCTTG. Primer
efficiencies (E%) were confirmed to be between 90 and
110%. Primers were confirmed to be specific based upon
melting profiles:
Gene Forward Reverse E%
SFRS11 AAATACCACCCAAC
AGTTT
AAGCCCTATACAGA
TGGAT
101
EHBP GAGTCTCCAATATCAT
CAGTAAGC
ACACATGCCACGA
TCAATG
96
CXCL2 CGCTGTCAATGCCT
GAAGAC
ACACTCAAGCTCTGGAT
GTTCTTG
101
IL12B TGGTTTGCCATCGTTT
TGCTG
ACAGGTGAGGTTCACTG
TTTCT
99
The total volume for each reaction was 20 µl and included
10 µl Forget-Me-Not EvaGreen qPCR Master Mix (Biotium
Frontiers in Aging Neuroscience | www.frontiersin.org 2 August 2020 | Volume 12 | Article 256
fnagi-12-00256 August 13, 2020 Time: 11:11 # 3
Pollock et al. Gene Expression Changes With ApoE
Inc., Ca, United States), 1 µl of each appropriate primer
(10 µM), 4 µl of nuclease free water, and 4 µl of template
cDNA. Each PCR reaction also included a reverse transcription
negative control to confirm the absence of genomic DNA in
triplicate and a non-template negative control to confirm the
absence of primer dimerization in triplicate. Real-time qPCR
was run on a LightCycler 96 (Roche, Basel, Switzerland). The
cycling conditions were 1 cycle of denaturation at 95◦C for
2 min, followed by 40 cycles of amplification (95◦C for 5 s,
55◦C for 10 s, and 72◦C for 15 s) and one cycle of product
melting (95◦C for 10 s, 65◦C for 60 s, and 97◦C for 1 s).
All samples were amplified in triplicate, and the Cq value for
each reaction was determined by the LightCycler 96 SW1.1.
Relative differences in expression between treatments were
determined by the LightCycler 96 SW1.1 and confirmed with the
11 Ct method.
RNA-Sequencing, Mapping, and Analysis
RNA-Sequencing
RNA-sequencing was performed by the Molecular Research
Core Facility at Idaho State University (Pocatello, ID).
All samples were sequenced using an Illumina HiSeq4000
Sequencer. Reads of 1 × 75 bp were demultiplexed and
adapter sequences were removed using Trim Galore v0.5.01.
Trimmed reads were then assessed for quality using FASTQC
v0.11.82. Reads were then mapped to a mouse reference
genome (version GRCm38.p6) using Hisat2 v2.1.0 (Kim et al.,
2015). Gene counts were determined using HTSeq v0.11.0
(Anders et al., 2015) after which, counts were normalized
using the median-of-ratios method with Deseq2 v1.22.2 (Love
et al., 2014). Deseq2 was then used to calculate p-values
using a Wald test with a Benjamini-Hochberg post hoc
correction. Genes with an adjusted p-value < 0.05 and a
fold-change >2 were considered to be differentially expressed.
Differentially expressed genes (DEGs) were enriched for
gene ontologies (GO) using PANTHER3. Analyses were
conducted to assess biological processes, molecular functions,
and cellular components.
The data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus and are accessible through
GEO Series accession number GSE1534544.
Gene Ontology Analysis
A list of every influenced gene and their respective fold
changes was imputed into the PANTHER classification system
(Shannon et al., 2003; Bindea et al., 2009). Statistical enrichment
tests were performed against the musculus genome, and the
Bonferroni correction was used. This process was performed
for biological processes and pathways (Mi et al., 2019a), and
the respective outputs were used. All data were statistically
significant with a corrected p-value < 0.05. In addition,
raw data was used to create a list of all genes upregulated
1https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/
2www.bioinformatics.babraham.ac.uk/projects/fastqc/
3pantherdb.org
4https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153454
by either nApoE31−151 or nApoE41−151 and a separate list
of all genes downregulated by nApoE1−151 fragments was
imputed into the PANTHER classification system (Mi and
Thomas, 2009; Mi et al., 2019b) and a functional classification
analysis was performed.
Statistical Analysis
Transcriptome data was used for analysis by averaging three
independent measurements. Treatment group data was then
referenced as a percent fold change increase from controls.
Data was segregated and organized by gene and treatment
group. The organization of data was to utilize the nApoE41−151
(E4 group) as a standard, organizing the data by highest to
lowest change for the E4 treatment group and aligning the
fold change for the nApoE31−151 (E3 group) to those values
for a matched pairs system. Data was then pulled into the
statistical analysis program, R, as a.csv file and checked for
normality assumptions using a Shapiro-Wilks Normality test
on each treatment group. Data failed to conform to normality.
A Spearman Rank Correlation was used as opposed to Pearson’s
Correlation due to the lack of normality in data and extreme
values. The Spearman Rank Correlation was then run on the top
500 highest fold change genes for the E4 group in comparison
to the matched genes in the E3 group to identify similarities in
trends. The resulting rho value was then referenced alongside
data to generate Figure 6.
Confocal Microscopy
Following treatment studies, BV2 cells were fixed by incubating
cells in 4% paraformaldehyde for 23 min. For antibody labeling,
cells were washed with 0.1 M Tris–buffered saline (TBS),
pH 7.4, and pretreated with 3% hydrogen peroxide in 10%
methanol to block endogenous peroxidase activity. Slides were
subsequently washed in TBS with 0.1% Triton X-100 (TBS-A)
and then blocked for 30 min in TBS-A with 3% bovine serum
albumin (TBS-B). Slides were further incubated overnight at
room temperature with the anti-His rabbit antibody (1:5,000).
Following two washes with TBS-A and a wash in TBS-B,
slides were incubated with the anti-rabbit HRP-conjugated
secondary antibody. Visualization was accomplished by using
a tyramide signal amplification kit (Molecular Probes, Eugene,
OR, United States) consisting of Alexa Fluor 488-labeled
tyramide (green, Ex/Em = 495/519). Slides were mounted
using ProLong Gold Antifade Mountant with DAPI (Molecular
Probes). Images were taken with a Zeiss LSM 510 Meta
system combined with the Zeiss Axiovert Observer Z1 inverted
microscope and ZEN 2009 imaging software (Carl Zeiss, Inc.,
Thornwood, NY, United States). Confocal Z-stack and single
plane images were acquired with an Argon (488 nm) and a
HeNe (543 nm) laser source. Z-stack images were acquired
utilizing the Plan-Apochromat 63 × /NA 1.4 and alpha Plan-
Fluar 100 × /NA1.45 Oil objectives and with the diode
(405 nm) and Argon (488 nm) laser sources, emission band
passes of 505–550 nm for the detection of the nApoE1–151
(green channel, Alexa Fluor 488). Orthogonal projection images
were constructed from Z-stacks in order to demonstrate the
staining is nuclear.
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RESULTS
Confirmation of Nuclear Localization of
Amino-Terminal Fragments of apoE in
BV2 Microglial Cells
Our previous findings have demonstrated the nuclear localization
of amino-terminal fragments of apoE4 within microglia both
in vivo, in the AD brain and in vitro following exogenous
treatment of BV2 microglia cells (Love et al., 2017). To confirm
and extend these findings, we exogenously treated BV2 microglia
cells with both nApoE31−151 and nApoE41−151 fragments, which
differ by a single amino acid (C→R). As shown in Figure 1,
uptake and trafficking to the nucleus was apparent for both
fragments, based on orthogonal projections taken from Z-stack
images (Figure 1, crosshairs, panels B and G). These results are
consistent with our previous findings (Love et al., 2017).
Transcriptome Analysis of BV2 Microglia
Cells Following Treatment With
ApoE41−151
We hypothesize the nApoE41−151 fragment is taken up by
microglia cells, traffics to the nucleus and may act as a
transcription factor leading to the change in gene expression.
For example, we have recently demonstrated that treatment of
BV2 cells with nApoE41−151 led to an increase in the expression
and release of the inflammatory cytokine, TNFα, a key trigger
of microglia activation (Pollock et al., 2019). In addition, we
demonstrated a specific binding interaction of nApoE41−151
FIGURE 1 | Orthogonal projections of confocal Z-stacks show nuclear localization of amino-terminal fragments of nApoE3 and E4 following exogenous treatment in
BV2 microglia cells. BV2 microglia cells were treated with either 25 µg/ml of nApoE31−151 (A–E) or with nApoE41−151 (F–J) for 24 h, fixed, and immunostained with
anti-His antibody to detect the localization of the apoE fragments. Confocal images were captured and Z-stacks were constructed showing the subcellular
localization of nApoE fragments. (A) High magnification merged image depicting nApoE31−151 in green and DAPI nuclear staining in blue. (B) Inset orthogonal
projection from red rectangle in panel A demonstrating nuclear localization of nApoE31−151 in a single BV2 microglia cell (crosshair). (C–E) Low magnification of
nApoE31−151 labeling with DAPI (blue, C), nApoE31−151 (green, D), and the overlapped image (E). All scale bars represent 10 µm. (F–J): Identical to panels A–E
except staining is representative of nApoE41−151 labeling. As with nApoE31−151, orthogonal images clearly demonstrate the nuclear labeling of nApoE41−151
(crosshair, G). Data are representative of five individual experiments.
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with the TNFα promoter region (Pollock et al., 2019). In
the current study, to test whether nApoE41−151 leads to the
induction of a broader array of inflammatory genes or other
pertinent genes, we performed a transcriptome analysis following
treatment of BV2 microglia cells with a sublethal concentration
of nApoE41−151. In this regard, a concentration of 25 µg/ml
showed no toxic effects following morphological examination
and LDH measurements. Cells were viable, healthy, and displayed
no indication of degeneration. LDH values for controls (relative
units) were 0.34 ± 0.096 SEM and 0.370 ± 104 SEM for treated
cells (N = 3, p-value = 0.80). In comparison to untreated control
BV2 cells nearly 8000 genes were determined to be differentially
expressed in the presence of nApoE41−151. The raw data file can
be accessed through Supplementary Data File S1. In addition,
files containing the raw data are available in the GEO repository
(GEO accession number, GSE153454). Although there were a
similar number of up-regulated and down-regulated genes, the
up-regulated genes had an average of a 6.6-fold change and
the down-regulated genes had an average of a 2.2-fold change.
Of the twenty most up-regulated genes, thirteen are known to
be involved in the inflammatory immune response (Table 1).
Biological processes, cellular components, molecular functions,
and pathways for each gene were assigned by the PANTHER
classification system (Figure 2). Involved cellular components
included the cell, the extracellular region, the membrane etc.
For each cellular component, there were many more associated
genes that were upregulated than downregulated. The biological
processes associated with genes differentially expressed in
the presence of nApoE41−151 included “cellular processes,”
“biological regulation,” “response to stimulus,” and “immune
system processes.” Each given biological process contained more
up-regulated genes than down-regulated genes, with “cellular
component organization” and “reproduction” being the least
up-regulated.
To verify transcriptome results, two genes were chosen and
independently verified by both RT-qPCR and ELISA assays. In
comparison to untreated controls, the differential expression of
two genes, CXCL2 and IL-12B, and their corresponding proteins
were confirmed with qPCR and ELISA (Figure 3). In this regard
following treatment of BV2 microglia cells with nApoE41−151,
both CXCL2 and IL-12B showed large increases in the fold
mRNA levels (Figures 3A,C) as well as in the secreted protein
in conditioned media (Figures 3B,D).
Many biological processes involved in the inflammatory
immune response were enriched by the nApoE41−151 fragment,
while many processes involved in cell division were down
regulated (Figure 4A). The molecular functions of regulated
genes included binding, catalytic activity and molecular
transducer activity. Each molecular function contained
more related up-regulated genes than down-regulated genes.
Numerous pathways related to the inflammatory immune
response were also enriched, including the apoptosis signaling
pathway (Figure 4B). Of the 72 genes in the apoptosis signaling
pathway (P00006), 66 were differentially expressed following the
introduction of nApoE41−151.
Transcriptome Analysis of BV2 Microglia
Cells Following Treatment With
ApoE31−151
We have previously documented the nuclear presence of
nApoE1−151 fragments within microglia of the human AD brain
TABLE 1 | The twenty most up-regulated genes and their functions following treatment of BV2 microglia cells with nApoE41−151.
Gene symbol Gene name Fold change p-value Function
Il12b Interleukin 12B 715 1.59E-89 Cytokine
Gm41236 Predicted gene, 41236 692 2.50E-14 lncRNA located near Acod1
Gbp5 Guanylate binding protein 5 672 3.79E-149 Innate immune response
Cxcl2 C-X-C Motif chemokine ligand 2 505 0 Chemokine, may suppress cell proliferation
IFI44 Interferon induced protein 44 479 1.48E-12 Immune response
Hc Hemolytic complement 459 3.93E-31 Innate immune response
Gm41236 Predicted Gene, 41236 337 5.74E-22 lncRNA located near Il7 gene
Acod1 Aconitate decarboxylase 1 322 0 Innate immune response
Adora2a Adenosine A2a receptor 277 3.66E-27 Adenosine signaling
1700025C18Rik RIKEN cDNA 1700025C18 gene 268 5.57E-10 lncRNA located near Cd40 gene
Lad1 Ladinin 1 262 4.94E-10 Cell structure
Gm41647 Predicted gene, 41647 225 2.34E-09 lncRNA near socs5 gene
Serpinb2 Serpin family B member 2 219 3.12E-09 Immune response
Il1b Interleukin 1 beta 216 0 Cytokine
Zbp1 Z-DNA Binding protein 1 213 1.46E-18 Interferon production
Gbp2 Guanylate binding protein 2 213 0 Innate immune response
LOC105245043 Uncharacterized LOC105245043 199 2.97E-09 Uncharacterized
Traf1 TNF Receptor associated Factor 1 187 0 TNF signal transduction
Il27 Interleukin 27 183 7.26E-71 Cytokine
Cd69 Cd69 Molecule 182 7.75E-50 Immune response
Of the known genes, >80% are associated with the immune system.
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FIGURE 2 | Functional categorization of up- and downregulated genes in BV2 microglia cells treated with an amino-terminal fragment of apoE4. BV2 cells were left
untreated or treated for 5 h with nApoE41−151 followed by total RNA purification and transcriptome analyses. The x-axis reflects the number of genes included for
each component, process, or function. For example, there were a total of 75 upregulated genes categorized as being a part of the cellular component. Functional
characterization was based on gene ontology (GO) annotations. Detailed information is shown in Supplementary Data File S1.
whose genotype was E3/E3 (Love et al., 2017). This would suggest
that nApoE31−151 may also act as a transcription factor leading
to changes in gene expression. Therefore, we also performed
an identical transcriptome analysis following treatment of BV2
microglia cells with nApoE31−151. It is important to note, that
in our previous study, treatment of nApoE31−151 did not lead to
cell toxicity (Love et al., 2017). As an initial approach, a broad
overview of the similarities and differences between the two
Frontiers in Aging Neuroscience | www.frontiersin.org 6 August 2020 | Volume 12 | Article 256
fnagi-12-00256 August 13, 2020 Time: 11:11 # 7
Pollock et al. Gene Expression Changes With ApoE
FIGURE 3 | Validation of transcriptome analysis by RT-PCR and ELISA of two identified upregulated genes. Two genes (CXCL2 and IL12B) identified by
transcriptome analyses to be significantly upregulated in BV2 cells following treatment with 25 µg/ml apoE41−151 (Table 1) were independently tested by RT-PCR
(A,C) or ELISA (B,D) in order to validate transcriptome findings. (A) BV2 cells were left untreated (control, green bar) or treated for 5 h with 25 µg/ml nApoE41−151
(blue bar), and RNA was extracted. RT-PCR analysis indicated a ∼1,500-fold increase in the expression of the inflammatory chemokine, CXCl2. Data are
representative of two independent experiments. (B) Secreted CXCl2 levels are significantly elevated following treatment of BV2 cells with nApoE41−151 (blue bar) as
compared to untreated controls (green bar). Data are representative of five independent experiments ± SEM *denotes p-value is <0.0001 between control and
nApoE41−151. (C) BV2 cells were left untreated (control, green bar) or treated for 5 h with 25 µg/ml nApoE41−151 (blue bar), and RNA was extracted. RT-PCR
analysis indicated a ∼388-fold increase in the expression of the inflammatory cytokine, IL-12b. Data are representative of two independent experiments.
(D) Secreted IL-12b levels are significantly elevated following treatment of BV2 cells with nApoE41−151 (blue bar) as compared to untreated controls (green bar).
Data are representative of eight independent experiments ± SEM *denotes p-value is < 0.00001 between control and nApoE41−151.
fragments was investigated. Treatment with nApoE31−151 led to
a differential upregulation of 2,262 genes by at least two-fold as
compared to 1,617 genes for nApoE41−151. Examining the top
20 genes that were induced by nApoE31−151, the representative
fold change ranged from 118- to 410-fold increased as compared
to non-treated control cells (Table 2). This is in contrast to a
representative fold change of 182- to 714-fold increase following
treatment by nApoE41−151 (Table 1). Of these 20 genes, 7 were
also in the top 20 for nApoE41−151-induced genes including
II12B, GM41236, GBP5, CXCl2, ACOD1, II1B, and GBP2. Of
the known top 20 genes, 70% are known to be associated with
immune function (Table 2).
Examining the enriched upregulated pathways, many of
those pathways are linked to the immune system, similar to
what was found for the nApoE41−151 fragment (Figure 5A).
These enriched upregulated pathways included cellular responses
to interferon-beta, regulation of viral life cycle, activation
of the innate immune response and defense to viruses
(Figure 5A). Our previous findings documented the toxicity of
the nApoE41−151 fragment, while the nApoE31−151 showed no
toxicity under identical treatment conditions. Therefore, like for
the nApoE41−151 (Figure 3B), we examined whether any genes
related to apoptosis were upregulated. As shown in Figure 5B,
there was a mix of anti-apoptotic genes induced (Bcl-2 related),
Bax inhibitor-1, and cellular inhibitors of apoptosis of protein
1 and 2 as well as pro-apoptotic genes including TNF related
protein, caspases, and cytochrome c (Figure 4B). Comparing the
fold enrichment between the two fragments, there was a 3.66-fold
increase in apoptosis signaling for nApoE41−151 fragment versus
2.68 for the nApoE31−151 (Table 3). However, these data cannot
explain the difference in our previously observed toxicity between
the two fragments (Love et al., 2017).
We also found similar fold increases in enrichment pathways
for both fragments with regards to Toll receptor signaling and
inflammation mediated by chemokine and cytokine signaling.
The only difference was that for integrin signaling pathways,
which was found to be specifically enriched (2.6-fold) for only
the nApoE41−151 fragment (Table 3).
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FIGURE 4 | Enriched biological processes and classification of apoptosis related genes regulated by an amino terminal fragment of nApoE4. BV2 cells were plated
onto 6-well plates to confluency and treated with or without ApoE41−151 for 5 h. Following treatment, total RNA was extracted and transcriptome analysis was
carried out as described in the Materials and Methods. (A) Data are expressed as fold enrichment of biological processes in BV2 microglia cells in the presence of
the ApoE41−151. Up-regulated processes are involved in the inflammatory immune response and the activation of BV2 microglia, while down-regulated processes
are involved in cell division. (B) Classification of genes in the apoptosis signaling pathway regulated by ApoE41−151. A total of 66 out of 72 genes in the apoptosis
signaling pathway (P00006) were influenced by the introduction of ApoE41−151. Enrichment and classification analyses were conducted using the PANTHER
classification system (pantherdb.org).
Looking at gene pathways downregulated, there was a
significant difference found between the two fragments.
The nApoE31−151 led to the down regulation of genes
related to aerobic respiration, mitochondrial translation,
and in mitochondrial respiratory chain complex 1 assembly
(Figure 5A). In contrast, many processes involved in cell division
were downregulated by the nApoE41−151 fragment (Figure 4A).
There was a significant degree of overlap in the genes
differentially expressed by both nApoE fragments. Following
a correlation analysis with a pool of the top 500 upregulated
nApoE41−151 and nApoE31−151 genes, the trajectories of the
fold changes were similar for many of the genes (S = 9651720,
ρ = 0.537, p-value < 0.00). These results indicate that while
the degree of change may not always align for the two
treatment groups, the direction of impact follows a weak positive
correlation path (Figure 6). In most cases, even when genes were
impacted in a similar fashion, the percent fold change in reference
to the control was much higher for the nApoE41−151 fragment
than for the nApoE31−151 fragment (Table 4).
Unique Genes Differentially Regulated
Following Treatment of BV2 Microglia
Cells With Either nApoE31−151 or
nApoE41−151
For the nApoE31−151 fragment, using a minimum of two-
fold increase/decrease change as our criteria, a total of 1,010
genes were upregulated by this fragment alone and 644 genes
downregulated (Figure 7). Examining the putative functions of
the top 10 unique upregulated genes, there was a diverse array of
genes involved in cellular processes including, mitosis, regulation
of the cytoskeleton, and cell signaling. The specific proteins
expressed included those for a dopamine receptor (DRD3 gene),
potassium channel (KCNF1 gene), collagen (COL6A1 gene),
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TABLE 2 | The twenty most up-regulated genes and their functions following treatment of BV2 microglia cells with nApoE31−151.
Gene symbol Gene name Fold change p-value Function
Gm41236 Predicted gene, 41236 410 7.59E-17 lncRNA located near Acod1
Cxcl2 C-X-C Motif chemokine Ligand 2 293 0 Chemokine, may suppress cell proliferation
Nos2 Nitric oxide synthase 2 290 1.10E-180 Produces nitric oxide
Gbp5 Guanylate binding protein 5 279 2.64E-198 Innate immune response
Csf3 Colony stimulating factor 3 224 9.65E-126 Cytokine
Il12b Interleukin 12B 221 2.56E-88 Cytokine
Gm33055 Predicted gene, 33055 201 4.22E-09 lncRNA with uncharacterized function
Acod1 Aconitate decarboxylase 1 191 0 Innate immune response
Il1b Interleukin 1 beta 180 9.60E-159 Cytokine
Gbp6 Guanylate binding protein 6 169 4.28E-41 Innate immune response
Gbp2 Guanylate binding protein 2 164 0 Innate immune response
II1f9 Interleukin 1F9 163 8.62E-12 Cytokine
Rsad2 Radical S-adenosyl methionine domain-containing protein 2 153 1.41E-93 Innate immune response
Ifi205 Interferon activated gene 205 149 1.13E-124 Innate immune response
Rnase10 RNase A family, 10 144 1.02E-07 Ribonuclease activity
Gm4951 Predicted gene, 4951 132 2.86E-20 Response to cytokine
Vcam1 Vascular cell adhesion molecule 1 130 6.19E-138 Immune response
Zfp811 Zinc Finger protein 811 122 1.72E-59 Nucleic acid binding
Kcnf1 Potassium voltage-gated channel modifier subfamily F member 1 118 6.50E-07 Putative voltage-gated potassium channel
Mefv MEFV Innate immunity regulator 118 6.56E-07 Innate immune response
Of the known genes, 70% are associated with the immune system.
G-protein signaling (HCAR1 gene), and actin stability (NES and
XIRP1 genes).
Using the same criteria of at least a two-fold increase/decrease
change in gene expression, a total of 81 genes were upregulated
by the nApoE41−151 fragment (Figure 7). For those genes
downregulated following treatment with nApoE41−151, a total of
21 genes were identified (Figure 7). Table 5 depicts the top 20
genes either upregulated or downregulated following treatment
of BV2 microglia cells with the nApoE41−151 fragment. In both
cases, these changes represent significantly fewer numbers of
genes differentially expressed as compared to nApoE31−151. For
the upregulated genes, examining the top twenty genes, only
6 (ETNK2, H2-Q6, EVA1B, NAT8, and KCNQ2) have known
functions. The top five genes (1700025C18Rik, 1700003M07Rik,
GM32846, GM36778, G930009F23RIK) representing a fold
change of 43 to 268-fold), have no known function. Other
genes in this top 20 list have been associated with a number of
different diseases including cancer (SRMS), epilepsy (KCNQ2),
frontotemporal dementia (TMEM252), and amyotrophic lateral
sclerosis (TMEM252).
DISCUSSION
ApoE is polymorphic with three major isoforms, ApoE2, ApoE3,
and ApoE4, which differ by single amino acid substitutions
involving cysteine-arginine replacements at positions 112 and
158 (Weisgraber et al., 1981). Harboring the APOE3 allele is
believed to neither increase nor decrease one’s risk of AD,
whereas inheritance of the APOE4 allele increases disease risk
upward to tenfold (Eisenstein, 2011). It is noteworthy that 65–
80% of all AD patients have at least one APOE4 allele (Saunders
et al., 1993; Farrer et al., 1997). The classic function of ApoE
resides in the CNS, where it is produced by a variety of
cells including microglia, and transports cholesterol to neurons
via apoE receptors, which are members of the low-density
lipoprotein (LDL) receptor family (Pitas et al., 1987; Michikawa
et al., 2000). Although ApoE3 and ApoE4 differ by a single
amino acid at position 112, none of the known actions of
ApoE4 sufficiently explain how harboring this allele enhances
AD risk. Recent evidence from our group has suggested that
this single amino acid change leads to enhanced proteolysis of
the full-length protein in several fragments, including a 151
amino-terminal fragment of ApoE4 (nApoE41−151). We have
demonstrated that this fragment is present in the human AD
brain where it localizes to nuclei of microglia cells (Love et al.,
2017). In addition, nApoE41−151 is toxic in vitro in BV2 microglia
cells and may induce toxicity by leading to the expression of
inflammatory genes including TNFA (Love et al., 2017; Pollock
et al., 2019). Moreover, nApoE41−151 binds directly to the
promoter region of TNFA and can induce expression and release
of the TNFA following treatment of BV2 microglia cells (Pollock
et al., 2019). The purpose of the present study was to determine
in greater detail the ability of nApoE41−151 to induce changes
in gene expression following treatment of BV2 microglia cells.
As a control, we directly compared transcriptome results with
an identical nApoE31−151 that differs by a single amino acid at
position 112 (C > R). It is noteworthy that we could not test the
role of an ApoE2 fragment in terms of changes in gene expression
because a 1-151 amino-terminal fragment of ApoE2 would be
identical to the nApoE31−151 fragment. Bearing this in mind, it is
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FIGURE 5 | Enriched biological processes and classification of apoptosis related genes regulated by an amino terminal fragment of nApoE3. BV2 cells were plated
onto 6-well plates to confluency and treated with or without nApoE31−151 for 5 h. Following treatment, total RNA was extracted and transcriptome analyses was
carried out as described in the Materials and Methods. (A) Data are expressed as fold enrichment of biological processes in BV2 microglia cells in the presence of
the nApoE31−151. Up-regulated processes are involved in the inflammatory immune response of BV2 microglia, while down-regulated processes are involved in
mitochondrial oxidative phosphorylation. (B) Classification of genes in the apoptosis signaling pathway regulated by nApoE31−151. Numerous genes involved in cell
signaling pathways were upregulated following treatment with the E3 fragment. Enrichment and classification analyses were conducted using the PANTHER
classification system (pantherdb.org).
TABLE 3 | Enriched pathways upregulated by nApoE31−151 and nApoE41−151.
Pathway Enrichment by E3
fragment
Enrichment by E4
fragment
Toll receptor signaling 5.22 6.5
Chemokine/cytokine signaling 3.3 3.38
Apoptosis signaling 2.68 3.66
Integrin signaling 2.6
difficult for us to speculate on what potential structural effects of
ApoE2 could potentially modulate gene expression. However, it
is possible that amino-terminal ApoE2 fragments may also have
an effect on gene expression, but further studies will be necessary
to address this issue.
Treatment of BV2 microglia cells with nApoE41−151 led
to the differential expression of a vast array of thousands
of genes including a 715-fold increase in the expression of
IL12B gene as well as a 504-fold increase in the CXCL1 gene,
both key mediators of inflammatory immune responses. We
independently confirmed the increase in gene expression and
protein secretion of IL12b, CxCl1 (Figure 3), and TNFA (Pollock
et al., 2019) in BV2 cells by RT-PCR and ELISA assays. Overall,
many biological processes involved in the inflammatory immune
response were enriched by the fragment, while many processes
involved in cell division were down regulated. In addition,
apoptotic pathways were enriched by the nApoE41−151 fragment
providing a possible link to the observed toxicity in vitro
(Love et al., 2017).
Examining the top five genes induced by nApoE41−151 and
their possible connection to AD, the top gene was IL12B, which
increased 715-fold following treatment of BV2 microglia cells
with nApoE41−151. This cytokine has been implicated in the AD
process. Elevated levels of the p40 subunit of IL-12 have been
detected in AD brains (Pitas et al., 1987), and in AD animal
models, inhibition of p40 alleviates the cognitive impairments
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FIGURE 6 | Gene expression following treatment with fragments displays similar patterns of upregulation. The scatterplot analysis displays a moderate positive
relationship between the nApoE31−151 and nApoE41−151 treatment groups (S = 9651720, ρ = 0.537, p-value < 0.00). Data is representative of three independent
trials that were averaged and expressed as a percentage change in comparison to the control versus each treatment. A Spearman Rank Correlation was utilized to
overcome dissonance in normality from extreme data points. Ellipses represent 0.5 and 0.95 confidence intervals and the dotted line is a linear trendline.
and AD-related pathology (Vom Berg et al., 2012; Tan et al.,
2014). Rs568408 and rs3212227 SNPs, which are located in IL-
12A and IL-12B, respectively, have recently been reported to
influence AD risk in the Han Chinese population (Zhu et al.,
2014). The GBP5 gene increased 672-fold following treatment
with nApoE41−151 and this gene belongs to the TRAFAC
class dynamin-like GTPase superfamily. The encoded protein
acts as an activator of NLRP3 inflammasome assembly and
has a role in innate immunity and inflammation (Latz et al.,
2013). The NLRP3 inflammasome is an important contributor
to inflammatory diseases, including AD (Latz et al., 2013;
Heneka, 2017; Ising et al., 2019). Finally, the CXCl2 gene
expression increased 505-fold following treatment. This gene is
part of a chemokine superfamily that encodes secreted proteins
involved in immunoregulatory and inflammatory processes.
The CXCl2 protein and its receptor has been identified in
AD patient brains and may promote Aβ-stimulated microglia
activation (Boddeke et al., 1999; Van Coillie et al., 1999;
El Khoury et al., 2003).
In summary, exogenous treatment of BV2 microglia cells with
nApoE41−151 led to the upregulation of thousands of genes and
of the top 20, 80% are associated with microglia activation and
inflammation. These data support a possible linkage between
harboring the APOE4 allele and inflammation that has long
been associated with AD (Streit, 2005; Graeber and Streit, 2010;
Heneka et al., 2014; Das and Chinnathambi, 2019).
We compared the transcriptome results of nApoE41−151 with
nApoE31−151 which differ by a single amino acid at position
112. It is noteworthy that in a previous study, we identified
TABLE 4 | The top 15 overlapping genes upregulated by nApoE31−151 and
nApoE41−151.
Gene symbol E3 Fold change E4 Fold change
Il12b 221 715
Gm41236 410 691
Gbp5 279 672
CXCl2 293 505
Ifi44 92 479
Hc 5.36 459
LOC102634900 53.2 337
Acod1 191 322
Adora2a 82.7 277
Lad1 30.2 262
Gm41647 86.3 225
Serpinb2 68.1 219
Il1b 180 216
Zbp1 102 213
Gbp2 164 213
nApoE31−151 in postmortem human AD sections, although
to a lower extent as to nApoE41−151 (Love et al., 2017). In
BV2 cells, although nApoE31−151 appears to somewhat traffic
to the nucleus, it does not lead to cell toxicity nor does it
lead to a change of morphology indicative of activation (Love
et al., 2017; Pollock et al., 2019). Therefore, we were somewhat
surprised at the number of genes differentially regulated by
the nApoE31−151 fragment. Of the top twenty genes induced,
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FIGURE 7 | Venn diagram demonstrating common and divergent gene
regulation between nApoE31−151 and nApoE41−151 fragments.
A comparison of genes regulated more than two-fold by treatment with
nApoE31−151 and nApoE41−151. nApoE31−151 regulated the expression of
1654 genes that were not regulated by nApoE41−151. Of these 1654 genes,
1010 were upregulated and 644 were downregulated. Conversely, there were
102 genes uniquely regulated by nApoE41−51. Of these 102 genes, 81 were
upregulated, and 21 were downregulated. There were 1673 genes that were
regulated by both nApoE41−151 and nApoE31−151. Also included are
common differentially expressed genes (DEGs) for both fragments including
1,062 induced DEGs and 591 repressed DEGs (orange intersecting region).
TABLE 5 | Top 20 genes differentially regulated by the nApoE41−151 fragment.
Genes upregulated Fold change Genes downregulated Fold change
1700025C18Rik 268 Adamtsl2 −38.0
1700003M07Rik 146 Treml1 −24.9
Gm32846 62.3 Zdhhc8 −20.1
Gm36778 42.7 Gm34741 −19.9
G930009F23Rik 38.9 Gm30624 −19.6
Etnk2 36.8 Gm38809 −18.4
H2-Q6 35.5 BE949265 −10.1
Eva1b 35.3 Gm26808 −9.35
Nat8 33.2 Gm34515 −7.94
Gm8075 31.5 Fam19a5 −7.61
Tmem252 31.3 Gm6416 −7.03
4930524O08Rik 29.6 Igdcc4 −6.51
LOC108168675 29.2 Pxt1 −5.61
Srms 28.0 4833415N18Rik −5.30
Kcnq2 27.8 Pnpla5 −5.24
LOC100862202 27.6 LOC102632901 −4.63
LOC108167381 25.7 Mcidas −3.82
Gm34542 25.6 Tpbgl −3.21
Gm26509 25.4 Apbb1 −2.87
A530046M15Rik 25.3 Shc2 −2.72
70% are involved in immune function. In addition, six of the
top twenty genes upregulated were listed in the top twenty
genes induced by the nApoE41−151 fragment (Tables 1, 2). Like
nApoE41−151, nApoE31−151 led to a 2.68-fold enrichment in
apoptotic pathways, compared to 3.66-fold for nApoE41−151
(Table 3). Therefore, at this time we cannot reconcile the lack of
cell death as caused by treatment with nApoE31−151 in BV2 cells
(Love et al., 2017) and the upregulation of apoptosis signaling
pathways shown in the present study. It is also important to note
that our read depth was sufficient so that results are not biased,
meaning that the differences in the significant genes that appear
in one treatment versus another are not due to a difference in
coverage, but that they are actually significant.
A significant difference between the two fragments was
that only nApoE41−151 led to enrichment in integrin signaling
pathways (2.6-fold). Another interesting difference was the
finding that the nApoE31−151 uniquely led to the downregulation
of pathways involved in mitochondrial function including
aerobic respiration, mitochondrial translation and mitochondrial
respiratory chain complex 1 assembly (Figure 5). Multiple lines of
evidence suggest that mitochondrial integrity and function, and
innate immunity are closely interlinked processes. Mitochondria
are intracellular organelles required for numerous cellular
functions including energy metabolism, regulation of reactive
oxygen species (ROS) signaling, Ca2+ homeostasis, and apoptosis
(Culmsee et al., 2018). Therefore, a potential consequence of
down regulating genes associated with mitochondrial function
may be a dampening of the production of ROS and an overall
effect of moving microglia away from activation.
We also examined those genes whose expression changed
with the treatment of nApoE31−151 but did not change with
the treatment of nApoE41−151 and vice versa. Using a criterion
of at least a two-fold change in expression, there were ∼16
times more genes differentially upregulated by nApoE31−151
(1,010 genes) in comparison to nApoE41−151 (81 genes). Many
of these nApoE31−151-induced genes appeared to be involved
in an array of microglia processes including regulation of the
cytoskeleton, cell signaling, and extracellular matrix pathways.
In addition, one gene of interest was uniquely downregulated
by nApoE31−151 by ∼20-fold. This gene, SLC25A11 encodes
for mitochondrial, 2-oxoglutarate/malate carrier (Monne et al.,
2013). A recent study demonstrated that this carrier plays
a key role in regulation of the NLRP3 inflammasome, a
multiprotein complex, which is involved in a pro-inflammatory
form of cell death (Shuvarikov et al., 2018). Thus, the
downregulation of SLC25A11 protein may prevent activation of
this inflammasome and thus limit this form of cell death as well
as subsequent inflammation.
In contrast to those genes specifically regulated by
nApoE31−151, many of the genes differentially expressed by
nApoE41−151 have unknown functions. For example, of the
20 top upregulated genes, only 6 (ETNK2, H2-Q6, EVA1B,
NAT8, and KCNQ2) have known functions. The top five
genes (1700025C18RIK, 1700003M07Rik, GM32846, GM36778,
G930009F23RIK) representing a 43-268-fold change), have
no known function. Although no known function has been
assigned to any of these top 5 genes, one gene where there is
existing evidence is 1700025C18RIK, which increased 146-fold
following nApoE41−151 treatment. 1700003M07Rik encodes
for AK005651 mRNA and exhibits decreased expression in
thymus and spleen in non-obese diabetic mice. A type 1 diabetes
susceptibility locus, IDD11, and recombination hotspot were
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found within this gene. As a result, this gene may play a
role in diabetes (Tan et al., 2010; Hamilton-Williams et al.,
2013). Limited data is also available on another relatively
unknown gene, G930009F23RIK upregulated 39-fold by the
nApoE41−151 fragment. G930009F23RIK is transcribed to
AK145170 lncRNA. Previous studies have shown AK145170
is upregulated 21-fold following treatment with negative
factor (Nef) in mouse astrocytes (Zhou et al., 2018). Nef
is a myristoylated, HIV-encoded protein released through
exosomes that induces the production of various cytokines and
chemokines in astrocytes to promote neuron death (van Marle
et al., 2004). The effects of HIV-1 infection, especially through
the neurotoxicity of Nef, may contribute to HIV-associated
neurocognitive disorders (HAND) pathogenesis (Torres-Munoz
et al., 2001). Thus, G930009F23RIK expression may play a role in
the pathogenesis of HAND.
It is interesting to speculate on what role these top
five genes may have and if they contribute somehow to
the toxicity produced by nApoE41−151, which was not
observed with nApoE31−151 (Love et al., 2017). Due to
the paucity of unique genes induced by nApoE41−151, we
were unable to analyze any enriched pathways, however,
the data did reveal two genes involved in the AD-presenilin
pathway and one gene involved in the AD-Aβ secretase
pathway. On the other hand, enriched pathways for
nApoE31−151, were easily calculated given the large number
of genes upregulated and included collagen biosynthesis
and modifying enzymes (5.17-fold enrichment), collagen
formation (4.34-fold enrichment), class A/1 Rhodopsin-like
receptors (2.54-fold enrichment), and GPCR ligand binding
(2.23-fold enrichment). Taken together, these results can
be interpreted to suggest that nApoE31−151 may play a
more physiological role in microglia cells as compared to
nApoE41−151, which may lead to activation, inflammation, and
activation of AD pathways.
CONCLUSION
Herein, we provide transcriptome data supporting a new role for
ApoE3 and E4 as regulators of gene expression. Traditionally,
ApoE has an important role in regulating the metabolism of
lipids by directing their transport, delivery, and distribution from
one cell type to another through ApoE receptors within the
CNS (Verghese et al., 2011). Our previous findings supported
a role for amino-terminal fragments of ApoE4 consisting of 1–
151 amino acids (nApoE41−151) that can traffic to the nucleus
and bind to enhancer elements such as for TNFα, leading to
expression, activation and cytotoxicity of BV2 microglia cells
(Love et al., 2017). Full-length ApoE4 was without effect in
this respect, and treatment of nApoE31−151 did not lead to
cellular toxicity. In the current study, we now extend these
findings and demonstrate nApoE41−151 and nApoE31−151 can
lead to large changes in gene expression following exogenous
treatment of BV2 microglial cells. Our results suggest that
while nApoE31−151 may serve a more physiological role in
this manner, nApoE41−151 may activate genes with a more
pathological purpose. These data support the hypothesis that
the link between harboring the APOE4 allele and dementia
risk could be enhanced inflammation through activation of
microglia to the inflammatory M1 phenotype (see below). Future
studies are warranted to understand the set of genes uniquely
upregulated by the nApoE1−151 fragment, many of which have an
unknown function at this time. BV2 cells are a well-characterized,
extensively employed model system for microglia. Studies have
demonstrated that BV2 cells are a valid substitute for primary
microglia in many experimental settings, including complex cell-
cell interaction studies (Henn et al., 2009). However, there are
clear limitations using these cells including that they are murine
in origin and represent transformed cells, which could change
their phenotype (Timmerman et al., 2018). Therefore, further
studies will be needed in human iPSC-induced microglia cells or
other primary cultures of microglia to confirm that similar sets of
genes are expressed in human microglia cells following treatment
with E3 or E4 fragments.
RNA transcriptome analyses in BV2 microglia cells following
sublethal treatment with nApoE41−151 indicated an upregulation
of almost 4,000 genes with 20 of these genes upregulated 182-
715-fold as compared to untreated control cells. The majority
of these 20 genes play a role in the immune response and
polarization toward the microglial M1 activation phenotype. For
example several studies have supported that a M1 phenotype is
characterized by the upregulation of proinflammatory pathways
including TNFα, IL-12, IL-1B, CCl2, whereas a shift to the
M2 antinflammatory phenotype leads to the downregulation of
genes such as CD86 and CD163 (Shin et al., 2014; Gensel and
Zhang, 2015; Yang et al., 2016; Li et al., 2019). Treatment of
BV2 cells with nApoE41−151 led to a similar pattern of gene
regulation supporting the conclusion of a conversion to a M1
phenotype. Recently, a strong case has been made for ApoE
as a pivotal regulator for microglia phenotypes (Krasemann
et al., 2017). In this regard, the authors identify a subset
termed microglia neurodegenerative phenotype (MGnD) that
is characterized by suppressed microglial homeostatic genes
such as P2ry12, Tmem119, Olfml3, Csf1r, Rhob, Cx3cr1, Tgfb1,
Mef2a, Mafb, Sall1 and upregulated inflammatory molecules
included Spp1, Itgax, Axl, Lilrb4, Clec7a, Csf1, and Apoe, The
authors concluded that as disease progresses, the gene expression
profile of microglia switches to MGnD type. We examined the
differential gene expression following treatment of BV2 cells
with the nApoE41−151 fragment in the context of this study
and found a similar increase in Axl (eight-fold), CCl2 (5.6-fold),
Lilrb4 (4.43-fold), and Spp1 (two-fold). On the other hand, we
found a similar decrease in Tmem119 (−2-fold), CSF1r (−1.11-
fold), Rhob (−1.8-fold), and Mafb (−8.22-fold). Therefore, we
believe our data support a similar phenotypic change to MGnD
in our model system suggesting that nApoE41−151 may lead to
a similar conversion of microglia in the AD brain. In a separate
study, a novel type of disease-associated microglia (DAM) was
characterized and was associated with beta-amyloid plaques in
AD, and is also present in ALS (Keren-Shaul et al., 2017). Their
analysis indicated that all of the microglia with a DAM signature
expressed CD11c and showed an upregulation of other genes
including CD9, Clec7a, and CD63 (Keren-Shaul et al., 2017). In
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the present study, we did not find a similar gene expression
profile or other DAM-type changes in BV2 cells treated with
nApoE fragments, and therefore, we do not believe nApoE41−151
switches microglia to this phenotype in the AD brain.
In conclusion, the nApoE41−151 fragment is a powerful
regulator of gene expression, leading to the upregulation of
numerous genes linked to inflammation associated with AD.
Therefore, preventing the nuclear localization of nApoE41−151,
perhaps through the use of structure-corrector molecules
(Chen et al., 2012; Mahley and Huang, 2012) may prevent nuclear
localization, blocking transcriptional effects and thus, preventing
the subsequent inflammation accorded by microglia in AD
(Webers et al., 2020).
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